Melasma

Researchers are evaluating whether Chitosan mouthwash can reduce the recurrence of black stains on teeth in children aged 6 to 12 years. The study aims to find out if using Chitosan mouthwash daily lowers the need for professional cleaning sessions and improves the appearance of teeth by decreasing black stain recurrence. This clinical trial is sponsored by Al-Azhar University and focuses on pediatric patients with black stains on their teeth. Participants will first undergo scaling and polishing dental cleaning, followed by a 3-month observation period. After this, scaling and polishing will be repeated, and the children will use Chitosan mouthwash daily for an additional 3 months. The study uses a crossover design where each participant serves as their own control before and after using the mouthwash. During the study, participants will visit the clinic every 6 weeks for checkups and data collection over a total of 36 weeks. Researchers will measure the recurrence of black stains as the primary outcome. The study will monitor participant adherence to the mouthwash and assess teeth appearance and stain recurrence during these visits to evaluate the mouthwash's effects.

Researchers are evaluating Autologous Adipose Cell Therapy to improve skin rejuvenation and hair restoration. This therapy aims to overcome the limitations of traditional fat grafting and dermal fillers by isolating early-stage fat cells for better distribution and longer-lasting effects. The study focuses on assessing the safety, feasibility, and effectiveness of this therapy for conditions like wrinkles, fine lines, skin elasticity loss, pigmentation, hair thinning, and hair loss. Participants will receive the Autologous Adipose Cells therapy treatment, which involves processing fat cells from their own body to enhance skin and hair appearance. The therapy is monitored by the primary investigator for up to 25 weeks to evaluate outcomes. This study includes only one treatment group receiving this biological intervention. During the study, participants will undergo various assessments including imaging, satisfaction surveys, and evaluation reports from the first visit before treatment through the last follow-up visit between weeks 16 and 25. The plastic surgeon will monitor treatment effects and safety over a six-month period. The total involvement spans from initial treatment to multiple follow-ups to track skin and hair improvements and participant satisfaction.

Researchers are studying the use of the AVAVA Device, a 1550nm Non-Ablative Fractional Laser, to treat various dermatologic conditions including acne, acne scars, wrinkles, pigment lesions, and skin texture disorders. The study aims to collect and analyze patient feedback on their overall experience with the device treatment. The primary focus is on responses to post-treatment questionnaires, while secondary measures include evaluations by physicians and patients regarding improvements and side effects. Participants will receive treatment using the AVAVA Device targeting their dermatologic condition. The study includes follow-up periods at 3, 6, and 12 months after the final treatment to assess outcomes. During these times, trained dermatologists will review before and after images, and both physicians and subjects will complete satisfaction and clinical improvement scales. The treatment process involves digital photography and adherence to specific skincare and sun exposure guidelines. Throughout the study, participants will complete questionnaires immediately after treatment and during follow-up visits to report their experience and tolerance of the procedure, including pain levels. Researchers will monitor the skin's response and improvements over time through imaging and clinical assessments. The study requires participants to comply with study instructions, maintain consistent skincare, and attend scheduled visits. The total participation duration spans from initial treatment through 12 months of follow-up.

This research is a clinical study designed as a single-blind randomized controlled trial to evaluate treatments for melasma, a pigmentation disorder causing brownish patches on the skin. The study aims to assess the effectiveness and safety of intradermal concentrated secretome injection, triple combination cream, and intradermal tranexamic acid injection in melasma patients. It also seeks to understand the quality of life of patients after triple combination cream therapy and to measure superoxide dismutase (SOD) levels. Participants are divided into three groups of 30 each: one receiving secretome injections, another using triple combination cream, and the third receiving tranexamic acid injections. The secretome and tranexamic acid groups also use 0.5% tretinoin cream for two weeks before treatment. The secretome group receives injections three times over 8 weeks, with evaluations every 4 weeks. The triple combination cream group applies the cream nightly with evaluations every 4 weeks. The tranexamic acid group receives injections every 2 weeks with evaluations at multiple timepoints. During the 12-week study, participants undergo physical exams, clinical photos, mMASI scoring, dermoscopy, Wood's lamp examination, mexameter measurements, and patient tolerability assessments at scheduled intervals. Data on melasma severity, melanin and erythema indices, and quality of life are collected and analyzed. The study includes monitoring for safety and treatment adherence, with all participants receiving facial wash and sunscreen as part of their regimen.

Researchers are evaluating the safety and effectiveness of a hybrid fractional laser to treat acne scars, especially in patients with darker skin tones (Fitzpatrick IV and V). Acne scarring, often caused by skin damage during healing, can negatively affect quality of life and mental health. Current treatments struggle with effectiveness and safety in skin of color, prompting this study to focus on a hybrid laser combining ablative and non-ablative components. The study involves two groups based on skin type: one with Fitzpatrick IV-V and another with Fitzpatrick I-III. Each participant receives up to three sessions of the Sciton Halo hybrid fractional laser, which uses two wavelengths to target different skin layers. Before treatment, participants receive education on the procedure and sun care, and may be prescribed hydroquinone or retinol to reduce the risk of hyperpigmentation. Treatment sessions include before and after photos, and participants complete surveys on quality of life and satisfaction. Participants will be involved for about eight months, with assessments at multiple points including baseline, 3, 5, and 8 months. These assessments measure changes in acne scar severity, patient satisfaction, and dermatology quality of life using standardized surveys. The study monitors tolerability and outcomes throughout, ensuring participants follow the treatment and follow-up schedule. The research aims to improve understanding of hybrid laser treatment effects in skin of color.

Researchers are evaluating a new cosmetic formula to treat facial hyperpigmentation caused by three conditions: mild to moderate melasma, mild to moderate acne-induced post-inflammatory hyperpigmentation, and solar lentigo. This open, single-center study aims to assess the product's effectiveness, cosmetic acceptability, and its impact on reducing stigma associated with these skin conditions. The study follows ethical guidelines and good clinical practices to ensure proper conduct and data analysis. The study involves applying the tested product twice daily, in the morning and evening, along with using sunscreen in the morning and at midday for three months. Participants are grouped based on their specific type of hyperpigmentation: melasma, acne-induced hyperpigmentation without active acne, or solar lentigo. Each participant will use the product under normal conditions, with before-and-after comparisons to evaluate changes. Participants will be assessed at the start and after 84 days to measure skin changes using various pigmentation scores specific to each condition. Researchers will also use colorimetry to quantify skin color changes. Safety data will be recorded but not statistically analyzed. The study expects to include about 20 patients per group and will observe participants throughout the three-month treatment period to monitor efficacy and tolerability.

This research aims to evaluate the effectiveness, cosmetic acceptance, and impact on stigmatization of a tested serum formula used twice daily for three months in adults with mild to moderate facial hyperpigmentation. The study focuses on three types of hyperpigmentation: melasma, acne-induced post-inflammatory hyperpigmentation, and solar lentigo. These skin conditions result from excess melanin production due to factors like genetics, hormones, inflammation, acne, and sun exposure. Participants are divided into three groups based on their condition: those with mild to moderate melasma, those with mild to moderate acne-induced hyperpigmentation without active acne, and those with solar lentigo. All groups apply the serum formula to their face twice a day for three months. This open-label, single-center study compares skin condition before and after treatment to assess changes. During the study, participants will undergo assessments including Investigator's Global Assessment scores, pigment severity indexes specific to each condition, and colorimetry measurements to quantify skin color changes. The study tracks changes from baseline to day 84 to evaluate treatment effects. The trial follows ethical guidelines and includes safety monitoring throughout the participation period.

Melasma is a common skin condition marked by brown or gray patches, mainly on sun-exposed areas like the face. It often affects people with darker skin tones and is more common in women. The exact cause of melasma is unknown but may involve genetics, sun exposure, hormones, and other factors. This trial studies treatments for refractory melasma, focusing on options combined with topical hydroquinone, to address challenges in managing this condition. The trial compares three treatment approaches: sessions with a fractional Erbium YAG laser every three weeks plus nightly topical hydroquinone 4% cream, intradermal tranexamic acid injections every three weeks alongside the same topical cream, and daily oral tranexamic acid tablets for three months with the topical cream applied each night. The laser uses a specific wavelength to target skin layers with minimal heat damage, while tranexamic acid works by reducing pigmentation through anti-inflammatory and anti-melanogenic effects. Participants will receive their assigned treatment over three months, with assessments focusing on the effectiveness of these combinations in treating refractory melasma. Researchers will monitor changes in pigmentation and treatment response. The study includes regular visits for treatment sessions and evaluations, ensuring careful observation of participant progress and treatment outcomes.

Melasma is a common chronic skin condition causing brown to gray-brown patches, primarily on the face, especially in adult women with certain skin types. This research compares two treatments for facial melasma: injectable platelet-rich fibrin (i-PRF), a platelet concentrate from the patient's own blood, and intradermal tranexamic acid (TA), a drug that may reduce pigmentation. The study aims to assess which treatment is safer and more effective for improving melasma. Adult female patients with mild to moderate symmetrical facial melasma will participate. Each participant's face will be split: one side will receive i-PRF injections prepared from their blood, and the other side will receive intradermal tranexamic acid injections. Both treatments will be given in five sessions spaced two weeks apart, alongside instructions to use sunscreen and avoid other facial treatments. Participants will be evaluated before treatment and 90 days later using various measures such as the modified Melasma Area and Severity Index (mMASI), skin imaging with the Antera 3D camera, physician assessments, patient satisfaction, and quality of life questionnaires. Safety will be monitored by recording any side effects like pain, redness, swelling, or bruising. This study is designed to provide detailed comparisons of efficacy and safety between these two treatments.

Researchers are evaluating if metformin can help reduce the dark patches of melasma in Latin American women. This clinical trial aims to determine whether taking metformin daily for three months improves melasma, by comparing two different doses to see if either dose helps with this skin condition. The study is sponsored by the University of Puerto Rico and focuses on adult women aged 21 years and older. Participants will take oral metformin tablets starting at 500 mg once daily for the first four weeks. If participants tolerate the medication well, their dose will increase to 500 mg twice daily for the remaining eight weeks. During the trial, participants are asked to avoid other melasma treatments and use sunscreen with SPF 30 or higher daily. The study involves two clinic visits: one at the beginning and one at the end of the 12-week period. Throughout the study, researchers will monitor changes in the modified Melasma Area and Severity Index (mMASI) score from the start to week 12 to assess treatment impact. Participants will receive a phone call from the research team to check on their progress and any side effects. The total participation time spans three months, with evaluations at the start and conclusion of the treatment period.